The USA government had an agreement of 100 million doses of the COVID-19 vaccine with the firm. The US government will be providing $2.1 billion for the development of the vaccine, clinical trails,, manufacturing and the delivery of the first batch of the vaccines.
The US will also have a further option for a supply of additional 500 million doses of the vaccine in the longer-term. GSK adds that if study data are postive, the companies can request US regulatory approval some time in 1H 2021.
To put a bit of a timeline on things, phase 1/2 of the study is expected to start in September with Phase 3 set to be conducted by the end of the year.
That’s another win for both firms after having struck a deal with the UK government earlier in the week.